The global CRISPR/Cas9
licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier & Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

Contact us

"This is transformative technology that allows the recoding of life and editing"

Emmanuelle Charpentier
ERS co-founder, patent co-owner
& 2020 Nobel prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Consisting of over 85 issued patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.
Learn more

Latest news

New CRISPR/Cas9 Licensing Agreement for ERS Genomics & CHUM Research Centre, Montreal
Posted on
New licence provides CHUM access to the ERS CRISPR/Cas9 patent portfolio. DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ — ERS Genomics Limited (‘ERS’) is ...
ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International
Posted on
Dublin, Ireland – 19/10/2023** – ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International, India’s leading Contract Research, Development ...
ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement
Posted on
ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 ...
ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement
Posted on
ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement License allows AlgenScribe to expand its research and development activities using ...
ERS Genomics & Santa Cruz Biotechnology Enter Into CRISPR/Cas9 Licensing Agreement
Posted on
License allows Santa Cruz Biotechnology to develop and commercialize products using CRISPR/Cas9. Dublin, Ireland and Dallas, Texas, 10 August 2023:  ...
Reflections on BIO International
Posted on
Over 20,000 Participants & A Lot to Talk About: Reflecting on Bio International Convention, Boston 2023.
ERS Genomics & Transomic Technologies enter into CRISPR/Cas9 Licensing Agreement
Posted on
License allows Transomic Technologies to develop and commercialize products using CRISPR/Cas9. Dublin, Ireland and Huntsville, AL, USA,  August 3, 2023:  ...
Manipulating the Fabric of Life
Posted on
Someone’s famous uncle once said, “With great power comes great responsibility.” Genome editing is an incredibly powerful technique with huge ...
SynBioBeta 2023
Posted on
 SynBioBeta 2023 With ERS’ Paul Carter  – Sr. Director Business Development & Licensing, North America https://ersgenomics.com/wp-content/uploads/2023/06/Paul-Carter-SynBioBeta-audiogram.mp4 SynBioBeta 2023: Time to scale ...
ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement
Posted on
ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement This License allows abm to develop and commercialize products using CRISPR/Cas9 ...